A revamped website has been launched by the General Optical Council. Research had found the largest proportion of visitors used a tool to search the GOC registers, which was given a prominent place on the homepage. The website has also been designed to be viewed on tablets and mobile devices.
Lucentis has been recommended as a treatment for some patients with visual impairment due to diabetic macular oedema in draft guidance by the National Institute for Health and Clinical Excellence (NICE). Manufacturer Novartis remained concerned it was limited to those with a retinal thickness of 400 micrometres or more. A final appraisal document was expected by the end of this year or early 2013.
Register now to continue reading
Thank you for visiting Optician Online. Register now to access up to 10 news and opinion articles a month.
Register
Already have an account? Sign in here